Karyopharm Therapeutics Bolsa (NASDAQ: KPTI)

Últimas noticias sobre Karyopharm Therapeutics (NASDAQ:KPTI) Bolsa

Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics Inc

KARYOPHARM THERAPEUTICS ORD

<h3>Gainers</h3>
<ul>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock increased by 13.4% to $3.9 during Monday's after-market session. The company's market cap stands at $165.5 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares moved upwards by 10.45% to $0.52. The company's market cap stands at $20.7 million. </li>
<li>Singular Genomics Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMIC#NASDAQ">OMIC</a>) shares rose 9.76% to $17.2. The company's market cap stands at $42.9 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares increased by 5.81% to $0.74. The company's market cap stands at $50.6 million. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock moved upwards by 5.75% to $0.48. The market value of their outstanding shares is at $41.2 million. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares increased by 5.41% to $0.93. The company's market cap stands at $132.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) shares decreased by 15.4% to $14.0 during Monday's after-market session. The market value of their outstanding shares is at $830.4 million. </li>
<li>Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) stock decreased by 9.4% to $0.75. The market value of their outstanding shares is at $93.7 million. </li>
<li>Pennant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNTG#NASDAQ">PNTG</a>) stock decreased by 7.57% to $33.0. The company's market cap stands at $996.8 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock decreased by 6.26% to $0.13. The market value of their outstanding shares is at $14.6 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock decreased by 5.0% to $0.65. The company's market cap stands at $6.5 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock decreased by 5.0% to $0.72. The market value of their outstanding shares is at $34.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APLM

BNGO

CGTX

IGMS

KPTI

NIVF

OMIC

PNTG

RPTX

12 Health Care Stocks Moving In Monday's After-Market Session

Karyopharm Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kpti#NASDAQ">KPTI</a>) has been beaten down lately with too much selling pressure. While the stock has lost 12.1% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.
<h2>Here is How to Spot Oversold Stocks</h2>
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock&#39;s price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
<h2>Here&#39;s Why KPTI Could Experience a Turnaround</h2>
The RSI reading of 28.75 for KPTI is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.
The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for KPTI has increased 19.5%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, KPTI currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock&#39;s potential turnaround in the near term.
<a href="https://www.zacks.com/stock/news/2332006/down-12-14-in-4-weeks-here-s-why-karyopharm-therapeutics-kpti-looks-ripe-for-a-turnaround?cid=CS-BENZ-FT-tale_of_the_tape|rsi-2332006">To read this article on Zacks.com click here.</a>

Biotech

Earnings

News

Penny Stocks

Technicals

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround

HC Wainwright &amp; Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and maintains $7 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target

RBC Capital analyst Brian Abrahams reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and maintains $3 price target.

RBC Capital Reiterates Outperform on Karyopharm Therapeutics, Maintains $3 Price Target

Baird analyst Mitch Collett maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and lowers the price target from $8 to $5.

Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $5

Guidance

Karyopharm Revises FY24 Total Revenue Outlook From $140M - $160M To $145M - $160M, Est $145.44M

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 31.03 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $42.786 million which beat the analyst consensus estimate of $36.179 million by 18.26 percent. This is a 13.86 percent increase over sales of $37.579 million the same period last year.

Earnings Beats

Karyopharm Therapeutics Q2 2024 GAAP EPS $(0.20) Beats $(0.30) Estimate, Sales $42.786M Beat $36.179M Estimate

HC Wainwright &amp; Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and lowers the price target from $8 to $7.

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $7

HC Wainwright &amp; Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and maintains $8 price target.

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target

Events

Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses from SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024

Offerings

Karyopharm Therapeutics Files For Shelf Registration Of Up To 45.8M Shares Of Common Stock By Selling Stockholders

Financing

Karyopharm Announces Refinancing Transactions $148M Of Existing Convertible Notes Due In 2025 To Be Exchanged for $111M Of New Convertible Notes Due In 2029 And Warrants, Issues New $100M Senior Secured Term Loan due in 2028a

Health Care

Karyopharm Therapeutics Reaffirms 2024 Revenue Guidance Of $140M-$160M Versus Consensus Of $146.52M, Including U.S. XPOVIO Net Product Revenue Guidance of $100M-$120M

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 6.67 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $33.126 million which missed the analyst consensus estimate of $34.473 million by 3.91 percent. This is a 14.40 percent decrease over sales of $38.698 million the same period last year.

Earnings Misses

Karyopharm Therapeutics Q1 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $33.126M Miss $34.473M Estimate

Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates"
NEWTON, Mass., April 24, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected for presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024&nbsp;ASCO Annual Meeting) being held May 31 - June 4 in Chicago, IL. The Company is pleased to have received an invitation to present updated Endometrial Cancer data during a special session called "ASCO Plenary Series: Rapid Abstract Updates."
A highlight at the 2024 ASCO Annual Meeting includes a rapid oral abstract update of long-term follow-up of selinexor maintenance in patients with TP53wt advanced or recurrent endometrial cancer – a pre-specified subgroup analysis from the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study.
"As we follow the endometrial cancer patients whose tumors are TP53wt and evaluate the long-term benefit, our confidence for selinexor to provide meaningful benefit for patients continues to grow," said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm. "We are excited about the advancement of our three, phase three programs in areas of high unmet need in endometrial cancer, myelofibrosis, and multiple myeloma."
Details for the 2024 ASCO Annual Meeting abstracts are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Abstract Title</td>
<td colspan="1" rowspan="1">Presentation Type</td>
<td colspan="1" rowspan="1">Abstract #</td>
<td colspan="1" rowspan="1">Session Date/Time</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Endometrial Cancer</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Updates on Abstract 427956: Long-Term Follow up of Selinexor Maintenance in Patients with TP53wt Advanced or Recurrent Endometrial Cancer—A Pre- Specified Subgroup Analysis from the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study (Rapid abstract update presentation following July 25, 2023 Plenary Series)</td>
<td colspan="1" rowspan="1">Rapid Oral</td>
<td colspan="1" rowspan="1">427956</td>
<td colspan="1" rowspan="1">
June 1, 2024 &nbsp;
12:30pm-1:30pm CDT
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Phase 3 Dose Selection for Selinexor in TP53wt Endometrial Cancer Based on Exposure-Response Analysis</td>
<td colspan="1" rowspan="1">Poster</td>
<td colspan="1" rowspan="1">5594</td>
<td colspan="1" rowspan="1">
June 3, 2024 &nbsp;
9:00am – 12:00pm CDT
</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Myelofibrosis</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Phase 3 Trial Design: Randomized Double-Blind Study Evaluating Selinexor, an XPO1 inhibitor, Plus Ruxolitinib in Jaki- Naïve Myelofibrosis</td>
<td colspan="1" rowspan="1">Poster</td>
<td colspan="1" rowspan="1">TPS6594</td>
<td colspan="1" rowspan="1">
June 3, 2024 &nbsp;
9:00am – 12:00pm CDT
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Phase 2 Study Trial Design: Evaluating Selinexor Monotherapy in Patients with Jaki-Naïve Myelofibrosis and Moderate Thrombocytopenia</td>
<td colspan="1" rowspan="1">Poster</td>
<td colspan="1" rowspan="1">TPS6593</td>
<td colspan="1" rowspan="1">
June 3, 2024 &nbsp;
9:00am – 12:00pm CDT
</td>
</tr>
</tbody>
</table>
</figure>
About XPOVIO&#xAE; (selinexor) XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology indications, including: (i) in combination with Velcade&#xAE; (bortezomib) and dexamethasone (XVd) in patients with multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in patients with heavily pre-treated multiple myeloma; and (iii) in patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO (also known as NEXPOVIO&#xAE; in certain countries) has received regulatory approvals in a growing number of ex-U.S. territories and countries, including&nbsp;Europe, the&nbsp;United Kingdom,&nbsp;South Korea,&nbsp;Israel,&nbsp;Singapore,&nbsp;Hong Kong, Mainland China,&nbsp;Australia,&nbsp;Canada,&nbsp;Taiwan&nbsp;and&nbsp;Macau&nbsp;and is marketed in those areas by Karyopharm's global partners. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high unmet need cancer indications, including in endometrial cancer and myelofibrosis.

Karyopharm Announces Presentations In Endometrial Cancer And Myelofibrosis At The 2024 American Society Of Clinical Oncology Annual Meeting

Onco360&#xAE;, the nation's largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Karyopharm's product XPOVIO&#xAE; (selinexor), a first-in-class, XPO-1 inhibitor. XPOVIO is approved in multiple oncology indications, including: (i) in combination with Velcade&#xAE; (bortezomib) and dexamethasone (XVd) in patients with multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in patients with heavily pre-treated multiple myeloma; and (iii) in patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.
"Onco360 is excited to expand our partnership with the team at Karyopharm and become the preferred national specialty pharmacy partner for XPOVIO," said Benito Fernandez, Chief Commercial Officer.
Multiple myeloma is an incurable hematological malignancy involving plasma cells. Only 50 percent of patients diagnosed with multiple myeloma survive past five years following initial diagnosis. The National Cancer Institute estimates that in 2018, approximately 30,770 new patients were diagnosed with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cancer.gov%2Ftypes%2Fmyeloma&amp;esheet=53909745&amp;newsitemid=20240313022739&amp;lan=en-US&amp;anchor=multiple+myeloma&amp;index=1&amp;md5=ce1c3e2deb33edd4d5f821b12a147fcd">multiple myeloma</a> in the U.S.1 Unfortunately, most multiple myeloma patients will relapse following the first complete remission and often require continuous treatment to prevent disease progression. Previously, there were no U.S. Food and Drug Administration (FDA)-approved products or regimens for patients with relapsed or refractory multiple myeloma who failed treatment with lenalidomide, pomalidomide, bortezomib, carfilzomib, and/or daratumumab.
XPOVIO is manufactured by Karyopharm Therapeutics, and has received multiple approvals from the U.S. FDA since 2019.2 XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO-1.
Please see the full <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.karyopharm.com%2Fwp-content%2Fuploads%2F2019%2F07%2FNDA-212306-SN-0071-Prescribing-Information-01July2019.pdf&amp;esheet=53909745&amp;newsitemid=20240313022739&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=2&amp;md5=9a96ea7fb0a80a212c8564264ce8116d">Prescribing Information</a> for XPOVIO

Onco360 Selected As The Preferred National Specialty Pharmacy Partner For Karyopharm's Product XPOVIO, A First-In-Class, XPO-1 Inhibitor

HC Wainwright &amp; Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and lowers the price target from $10 to $8.

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $8

Karyopharm Sees 2024 Total Revenue $140M-$160M vs $152.02M Est.

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.30) by 20 percent. The company reported quarterly sales of $33.75 million which missed the analyst consensus estimate of $35.40 million by 4.68 percent. This is a 0.50 percent increase over sales of $33.58 million the same period last year.

Karyopharm Therapeutics Q4 2023 GAAP EPS $(0.36) Misses $(0.30) Estimate, Sales $33.75M Miss $35.40M Estimate

H.C. Wainwright analyst Edward White maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price target of $8...

Buy Rating for Karyopharm on Strong Xpovio Clinical Data and Favorable Safety Profile

Analyst Jonathan Chang from Leerink Partners reiterated a Hold rating on Karyopharm Therapeutics (KPTI – Research Report) and keeping the price tar...

Hold Rating on Karyopharm Amid Competitive Landscape and Pending Data Outcomes

RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price target of $3.0...

Karyopharm Therapeutics (KPTI) Receives a Buy from RBC Capital

Karyopharm Therapeutics Q2 2024 Earnings Preview

Karyopharm Therapeutics GAAP EPS of -$0.20 beats by $0.11, revenue of $42.8M beats by $6.59M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Karyopharm Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kpti-stock-quote/">KPTI</a>) just reported results for the second quarter of 2024.<ul><li>Karyopharm Therapeutics reported earnings per share of -20 cents. This was above the analyst estimate for EPS of -30 cents.</li><li>The company reported revenue of $42.79 million.</li><li>This was 18.26% better than the analyst estimate for revenue of $36.18 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/kpti-stock-earnings-karyopharm-therapeutics-for-q2-of-2024/">KPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Beats Revenue for Q2 2024

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report), with a price ta...

Barclays Keeps Their Buy Rating on Karyopharm Therapeutics (KPTI)

Analyst Jonathan Chang of Leerink Partners maintained a Hold rating on Karyopharm Therapeutics (KPTI – Research Report), retaining the price target...

Karyopharm Therapeutics: A Cautious Hold Amid Steady Performance and Pipeline Uncertainties

Karyopharm Therapeutics Inc. (KPTI) Q2 2024 Earnings Call Transcript

Karyopharm Therapeutics (KPTI) has shared an update. Michael Mason has announced his resignation as Executive Vice President, Chief Financial Offic...

Michael Mason Resigns as CFO of Karyopharm Therapeutics

Press Releases

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

Karyopharm to Participate at the Jefferies Global Healthcare Conference

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

Comments

Karyopharm Therapeutics

Noticias

Últimas noticias sobre Karyopharm Therapeutics (NASDAQ:KPTI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL